SLC5A2 and diabetes mellitus: Specifically, in subjects with diabetes and heart failure with reduced ejection fraction, SGLT2 inhibitors are recommended (class I, level A evidence), with specific recommendations for empagliflozin or dapagliflozin in subjects with left ventricular ejection fraction over 40% [6].